- Price
- $25.41
- Day
- +1.52%
- Mkt Cap
- $144.82B
- 52W Range
- $23.58 – $28.75
- Volume
- 61.32M
- Beta
- 0.28
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
Read full article
Pfizer beat Wall Street estimates for second-quarter profit on Tuesday, driven by strong demand for its blood thinner, Eliquis.
Read full article
With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
Read full article
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 700 points on Tuesday.
Read full article
Pfizer Inc. (NYSE:PFE) will release its second quarter earnings report before the opening bell on Tuesday, Aug. 4.
Read full article
Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.
Read full article
Pfizer Inc. (PFE) Q2 2026 Earnings Call Transcript
Read full article
Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue...
Read full article
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter, delivering on our financial commitments and adva.
Read full article
Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported adjusted earnings of $0.77 per share for the quarter, above the $0.68 expected by analysts.
Read full article
Pfizer (PFE) came out with quarterly earnings of $0.77 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago.
Read full article
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read full article